Surface Functionalization of Nanocarriers with Anti-EGFR Ligands for Cancer Active Targeting.
Anti-EGFR nanocarriers hold promise for targeted cancer therapy, but further clinical validation is needed.
Where it sits
this study against the rest of the abs-201 corpusSummary and findings
This review examines the functionalization of nanocarriers with anti-EGFR ligands for targeted cancer therapy. It discusses various conjugation strategies and characterization techniques for nanoparticle systems. The focus is on improving drug accumulation in EGFR-overexpressing tumor cells.
Abstract
Active cancer targeting consists of the selective recognition of overexpressed biomarkers on cancer cell surfaces or within the tumor microenvironment, enabled by ligands conjugated to drug carriers. Nanoparticle (NP)-based systems are highly relevant for such an approach due to their large surface area which is amenable to a variety of chemical modifications. Over the past decades, several studies have debated the efficiency of passive targeting, highlighting active targeting as a more specific and selective approach. The choice of conjugation chemistry for attaching ligands to nanocarriers is critical to ensure a stable and robust system. Among the panel of cancer biomarkers, the epidermal growth factor receptor (EGFR) stands as one of the most frequently overexpressed receptors in different cancer types. The design and development of nanocarriers with surface-bound anti-EGFR ligands are vital for targeted therapy, relying on their facilitated capture by EGFR-overexpressing tumor cells and enabling receptor-mediated endocytosis to improve drug accumulation within the tumor microenvironment. In this review, we examine several examples of the most recent and significant anti-EGFR nanocarriers and explore the various conjugation strategies for NP functionalization with anti-EGFR biomolecules and small molecular ligands. In addition, we also describe some of the most common characterization techniques to confirm and analyze the conjugation patterns.
Background
The study addresses the challenge of effectively targeting cancer cells by utilizing overexpressed biomarkers such as EGFR. Active targeting via ligand-conjugated drug carriers is considered more specific than passive targeting, which has been debated for its efficiency. The development of nanocarriers with anti-EGFR ligands is crucial for enhancing drug delivery to tumor cells.
Methods
This is a review article that synthesizes existing research on the functionalization of nanocarriers with anti-EGFR ligands. It examines various conjugation strategies and characterization techniques but does not involve new experimental data or a specific study population.
Results
Not reported in abstract.
Interpretation
The review highlights the potential of anti-EGFR nanocarriers in improving targeted cancer therapy. However, as a review, it does not provide new experimental evidence or quantify the clinical impact. The findings are consistent with the notion that active targeting can enhance drug delivery, but the clinical significance remains to be validated in trials.
Key findings
- EGFR is frequently overexpressed in various cancer types.
- Nanoparticles offer a large surface area for chemical modifications.
- Active targeting is more specific and selective than passive targeting.
- Receptor-mediated endocytosis can enhance drug accumulation in tumors.
Limitations
- No new experimental data
- Review article only
- No quantitative findings
- Focus on existing literature